FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904004021> ?p ?o ?g. }

• W2904004021 abstract "We investigated the suppressive effect of siRNA-mediated co-inhibition of PD-1 and CTLA-4 expression on H22 hepatomas in mice. Murine H22 cells were cultured in vivo in ICR mice. An allograft tumor model was also established in another ICR mouse group. The tumor-bearing mice were randomly divided into four groups: control, single PD-1 siRNA, single CTLA-4 siRNA, and double PD-1 + CTLA-4 siRNAs. The survival time and physiological condition of the mice were observed after the injection of the siRNAs and placebo. The volume and weight of the solid tumor were measured to assess the inhibition of the tumor. To assess the effects of siRNAs on mouse immune function, the protein levels of IFN-γ and IL-10 in the blood and PD-L1 in the tumor and liver were determined using ELISA, and the mRNA levels of IFN-γ, PD-L1, PD-1, CTLA-4, IL-6 and Survivin in the tumor, liver and spleen were determined using quantitative RT-PCR. The ratios of Bax and Bcl-2 protein were determined via western blot to analyze the effect of siRNAs on tumor cell apoptosis. The anti-tumor effect appeared in all groups with siRNA-mediated inhibition. The tumor growth suppression was stronger in the group with double inhibition. The weight and volume of the tumors were significantly lower and the survival rate improved in the three siRNA groups. IFN-γ levels increased but IL-10 levels decreased in the blood of the siRNA group mice compared with the results for the control group. In the tumor and spleen tissue, the IFN-γ levels significantly increased, but in the liver tissue they significantly decreased in the three siRNA groups. The results of quantitative RT-PCR showed that the mRNAs for PD-1 and CTLA-4 were downregulated in spleen tissue in the three siRNA groups, while the PD-L1 mRNA and protein levels increased significantly in the tumor, but decreased in the liver. Survivin and IL-6 mRNA levels decreased in the tumor. Western blot results showed that ratio of Bax and Bcl-2 had significantly increased. These results indicated that downregulating PD-1 and CTLA-4 could increase the body’s immune response and promote apoptosis of tumor cells. Co-inhibiting the expressions of PD-1 and CTLA-4 can effectively suppress the growth of H22 hepatoma and promote the apoptosis of tumor cells in mice. Blocking PD-1 and CTLA-4 can improve the vitality of T cells, and improve the immune environment and response." @default.
• W2904004021 created "2018-12-22" @default.
• W2904004021 creator A5008726615 @default.
• W2904004021 creator A5018943067 @default.
• W2904004021 creator A5076350219 @default.
• W2904004021 creator A5082990413 @default.
• W2904004021 date "2018-12-01" @default.
• W2904004021 modified "2023-10-17" @default.
• W2904004021 title "The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice" @default.
• W2904004021 cites W1816311090 @default.
• W2904004021 cites W1971422121 @default.
• W2904004021 cites W2004222531 @default.
• W2904004021 cites W2012972418 @default.
• W2904004021 cites W2016712307 @default.
• W2904004021 cites W2028376975 @default.
• W2904004021 cites W2037610638 @default.
• W2904004021 cites W2039123767 @default.
• W2904004021 cites W2060407805 @default.
• W2904004021 cites W2061467047 @default.
• W2904004021 cites W2087482409 @default.
• W2904004021 cites W2098853737 @default.
• W2904004021 cites W2100725860 @default.
• W2904004021 cites W2104916182 @default.
• W2904004021 cites W2107033272 @default.
• W2904004021 cites W2123424099 @default.
• W2904004021 cites W2131577873 @default.
• W2904004021 cites W2146506192 @default.
• W2904004021 cites W2156268588 @default.
• W2904004021 cites W2272278257 @default.
• W2904004021 cites W2290119977 @default.
• W2904004021 cites W2418160059 @default.
• W2904004021 cites W2468444838 @default.
• W2904004021 cites W2494232439 @default.
• W2904004021 cites W2528303838 @default.
• W2904004021 cites W2560367415 @default.
• W2904004021 cites W2611383873 @default.
• W2904004021 cites W2625296602 @default.
• W2904004021 cites W2780555458 @default.
• W2904004021 cites W2790658892 @default.
• W2904004021 cites W2807322325 @default.
• W2904004021 cites W2018518654 @default.
• W2904004021 doi "https://doi.org/10.1186/s11658-018-0122-0" @default.
• W2904004021 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6295075" @default.
• W2904004021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30564277" @default.
• W2904004021 hasPublicationYear "2018" @default.
• W2904004021 type Work @default.
• W2904004021 sameAs 2904004021 @default.
• W2904004021 citedByCount "15" @default.
• W2904004021 countsByYear W29040040212019 @default.
• W2904004021 countsByYear W29040040212020 @default.
• W2904004021 countsByYear W29040040212021 @default.
• W2904004021 countsByYear W29040040212022 @default.
• W2904004021 countsByYear W29040040212023 @default.
• W2904004021 crossrefType "journal-article" @default.
• W2904004021 hasAuthorship W2904004021A5008726615 @default.
• W2904004021 hasAuthorship W2904004021A5018943067 @default.
• W2904004021 hasAuthorship W2904004021A5076350219 @default.
• W2904004021 hasAuthorship W2904004021A5082990413 @default.
• W2904004021 hasBestOaLocation W29040040211 @default.
• W2904004021 hasConcept C104317684 @default.
• W2904004021 hasConcept C150903083 @default.
• W2904004021 hasConcept C153911025 @default.
• W2904004021 hasConcept C185592680 @default.
• W2904004021 hasConcept C190283241 @default.
• W2904004021 hasConcept C203014093 @default.
• W2904004021 hasConcept C207001950 @default.
• W2904004021 hasConcept C21705690 @default.
• W2904004021 hasConcept C22615655 @default.
• W2904004021 hasConcept C2775975398 @default.
• W2904004021 hasConcept C2776090121 @default.
• W2904004021 hasConcept C2776415932 @default.
• W2904004021 hasConcept C2780931953 @default.
• W2904004021 hasConcept C502942594 @default.
• W2904004021 hasConcept C54009773 @default.
• W2904004021 hasConcept C54355233 @default.
• W2904004021 hasConcept C55493867 @default.
• W2904004021 hasConcept C81885089 @default.
• W2904004021 hasConcept C86803240 @default.
• W2904004021 hasConcept C8891405 @default.
• W2904004021 hasConceptScore W2904004021C104317684 @default.
• W2904004021 hasConceptScore W2904004021C150903083 @default.
• W2904004021 hasConceptScore W2904004021C153911025 @default.
• W2904004021 hasConceptScore W2904004021C185592680 @default.
• W2904004021 hasConceptScore W2904004021C190283241 @default.
• W2904004021 hasConceptScore W2904004021C203014093 @default.
• W2904004021 hasConceptScore W2904004021C207001950 @default.
• W2904004021 hasConceptScore W2904004021C21705690 @default.
• W2904004021 hasConceptScore W2904004021C22615655 @default.
• W2904004021 hasConceptScore W2904004021C2775975398 @default.
• W2904004021 hasConceptScore W2904004021C2776090121 @default.
• W2904004021 hasConceptScore W2904004021C2776415932 @default.
• W2904004021 hasConceptScore W2904004021C2780931953 @default.
• W2904004021 hasConceptScore W2904004021C502942594 @default.
• W2904004021 hasConceptScore W2904004021C54009773 @default.
• W2904004021 hasConceptScore W2904004021C54355233 @default.
• W2904004021 hasConceptScore W2904004021C55493867 @default.
• W2904004021 hasConceptScore W2904004021C81885089 @default.
• W2904004021 hasConceptScore W2904004021C86803240 @default.
• W2904004021 hasConceptScore W2904004021C8891405 @default.
• W2904004021 hasIssue "1" @default.

• next